2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases
US12195432B2 · kind B2 · utility
0Cited by
13References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 6, 2019 |
| Grant date | Jan 14, 2025 |
| Priority date | — |
| Expiry date | Nov 5, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/05
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
A genus of compounds encompassed by formula (III) and their use is disclosed:The compounds activate Ppargc1a and, as a consequence, are useful for treating a variety of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, Huntington's disease, frontotemporal degeneration, dementia with Lewy bodies, motor neuron diseases, and a demyelinating disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.